 Celacade

Celacade is a non-pharmacological treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian-based biotherapeutics company Vasogen, for treatment of chronic heart failure and peripheral artery disease.At the World Congress of Cardiology in September 2006 the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) a phase III randomized, double-blind, placebo-controlled clinical trial involving some 2408 patients in 7 countries with left ventricular ejection fraction of 30% or less, reported that patients with a previous cardiovascular event receiving celacade where 39% less likely to die or be hospitalized due to a heart attack or stroke and tended to have improved quality of life.